Genmab — Maj 2025
-
as the first and only antibody-drug conjugate (ADC) approved in both Japan and the European Union (EU) for the treatment of recurrent or metastatic cervical cancer after prior therapy
Gen mab r evenue increase d 19% compared to the first quarter of 2024, to $715 million -
Genmab Announces Financial Results for the First Quarter of 2024 https://proinvestor.com/investornyt/1314391/genmab-announces-financial-results-for-the-first-quarter-of-2024
-
Genmab fastholder prognosen trods stærkt første kvartal pænt over konsensus https://proinvestor.com/investornyt/1314418/genmab-fastholder-prognosen-trods-staerkt-forste-kvartal-paent-over-konsensus
-
Genmab/Sydbank: Stærk toplinje og lavere end ventede omkostninger giver flot drift https://proinvestor.com/investornyt/1314431/genmab-sydbank-staerk-toplinje-og-lavere-end-ventede-omkostninger-giver-flot-drift
-
Genmab leverer et stærkt regnskab, som bør løfte aktien over 1.400 kr. på kort sigt. Selskabet er kun marginalt påvirket af told eller geopolitiske udfordringer, hvilket gør køb under 1.300 kr. attraktive for investorer med tillid til pipelinen – især lovende kandidater. Længere sigt kan positive data fra pipelinen drive kursen mod 2.000 kr. eller mere. Eksisterende succesprodukter genererer betydelige indtægter, og selskabets voksende likviditetsbeholdning styrker deres finansielle position,
-
Godmorgen
-
Genmabs topchef spår tre lægemiddelkandidater milliardsalg i dollar https://proinvestor.com/investornyt/1314693/genmabs-topchef-spar-tre-laegemiddelkandidater-milliardsalg-i-dollar
-
Genmab får sænket kursmål hos TD Cowen efter regnskab https://proinvestor.com/investornyt/1314700/genmab-far-saenket-kursmal-hos-td-cowen-efter-regnskab
-
Benzinga vs
EstimateMay 08, 2025
Genmab reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.23 by 34.78 percent. This is a 6.9 percent increase over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $715.00 million which missed the analyst consensus estimate of $748.58 million by 4.49 percent. This is a 19.08 percent increase over sales of $600.43 million the same period last year. -
Reuters - GMAB reported quarterly adjusted earnings of 31 cents per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of 29 cents. The mean expectation of four analysts for the quarter was for earnings of 24 cents per share. Wall Street expected results to range from 21 cents to 28 cents per share.
- Revenue rose 18.5% to $715.00 million from a year ago; analysts expected $756.69 million.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind